RAPT Therapeutics (RAPT) AI Stock Analysis

• Market Cap: $161.05M
• Dividend Yield: N/A
• Average Volume (3M): 751.76K
• Price to Earnings (P/E): ―
• Beta (1Y): 2.25
• Revenue Growth: N/A
• EPS Growth: -2.29%
• Country: US
• Employees: 68
• Sector: Healthcare
• Sector Strength: 71
• Industry: Biotechnology
• EPS (TTM): -3.12
• Shares Outstanding: 132,006,820
• 10 Day Avg. Volume: 1,350,244
• 30 Day Avg. Volume: 751,764
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• Price to Cash Flow (P/CF): -4.10
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: $6.00
• Price Target Upside: 391.80% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 3

RAPT Therapeutics' stock score reflects significant financial performance challenges, with no revenue and consistent losses weighing heavily. Technical indicators suggest a bearish trend. However, positive corporate events, including a partnership and secured funding, offer potential future upside, offsetting some of the current financial and technical weaknesses.

Positive Factors

Clinical Trials

The initiation of the Ph2b trial for RPT904 in food allergy is on track, indicating strong progress in the company's development pipeline.

Financial Stability

The company has a solid cash position of approximately $231 million, providing financial stability to support upcoming clinical milestones.

Licensing and Market Expansion

RAPT gaining worldwide development and commercialization rights to RPT904, excluding mainland China, Hong Kong, and Macau, represents a constructive step forward for their broader immunology pipeline.

Negative Factors

Financial Performance

RAPT recorded a full-year 2024 net loss of $3.19 per share, which was higher than the estimated net loss.

Market Competition

Pending competition from omalizumab biosimilars is expected to be an area of focus for investors.

Pricing Pressure

RAPT anticipates pricing erosion of 40% due to Xolair patent expiration and entry of biosimilar products, despite a potential price premium for RPT904.

RAPT Therapeutics Business Overview & Revenue Model

Company Description

RAPT Therapeutics is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing oral small molecule therapies for oncology and inflammatory diseases. Based in the United States, RAPT employs its proprietary drug discovery and development engine to create highly selective oral therapies aimed at key points in the immune system. The company’s lead product candidates include RPT193 and FLX475, which are designed to target specific pathways involved in the regulation of immune cells.

How the Company Makes Money

RAPT Therapeutics generates revenue primarily through strategic collaborations and partnerships with other pharmaceutical companies, as well as government grants and funding for its research initiatives. The company may also license its proprietary technology and intellectual property to other firms, providing another revenue stream. As RAPT advances its product candidates through clinical trials and towards potential commercialization, it anticipates generating revenue from the sale of its therapies upon obtaining necessary regulatory approvals.

RAPT Therapeutics Financial Statement Overview

Summary

RAPT Therapeutics has significant financial challenges, with no revenue generation and consistent operating losses. The income statement is notably weak, the balance sheet is strong due to low leverage, but cash flows are negative. Overall, these factors indicate sustainability concerns, common in biotechnology due to long development cycles.

Income Statement

RAPT Therapeutics has consistently reported negative net income and EBIT over the past years, indicating ongoing operational challenges. The company has not generated any revenue in recent years, which is a concern for sustainability. The lack of revenue and consistent losses contribute to a low score for the income statement.

Balance Sheet

The balance sheet shows a relatively strong equity position with a low debt-to-equity ratio, indicating conservative leverage. However, the lack of revenue generation poses a risk to the sustainability of the company's financial health. The equity ratio is high, showing a solid capital structure, but the ongoing losses are a concern.

Cash Flow

The company has consistently reported negative operating and free cash flows, pointing to challenges in generating cash from operations. The reliance on financing activities to support cash flow needs is notable. Despite this, the company has maintained a healthy cash position, mitigating some risk.

Breakdown
Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement		Total Revenue
0.00	0.00	1.53M	3.81M	5.04M
	Gross Profit
0.00	-3.55M	-1.28M	2.82M	5.04M
	EBIT
-136.10M	-127.06M	-85.80M	-69.21M	-53.21M
	EBITDA
-136.10M	-125.85M	-84.75M	-68.21M	-52.09M
	Net Income Common Stockholders
-129.87M	-116.80M	-81.88M	-68.21M	-52.89M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
231.06M	158.86M	249.07M	189.65M	111.51M
	Total Assets
240.32M	173.33M	266.21M	198.64M	118.97M
	Total Debt
4.49M	6.91M	8.99M	0.00	0.00
	Net Debt
-165.24M	-40.57M	-29.96M	-24.03M	-24.92M
	Total Liabilities
50.42M	26.29M	21.04M	12.26M	14.79M
	Stockholders Equity
189.90M	147.03M	245.17M	186.38M	104.18M
Cash Flow		Free Cash Flow
-83.42M	-98.17M	-71.62M	-61.78M	-40.89M
	Operating Cash Flow
-83.30M	-97.05M	-70.77M	-61.03M	-40.49M
	Investing Cash Flow
52.70M	104.13M	-45.49M	-81.35M	-87.44M
	Financing Cash Flow
152.85M	1.45M	131.18M	141.48M	75.46M

RAPT Therapeutics Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 1.22
• 50DMA: Positive
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For RAPT, the sentiment is Negative. The current price of 1.22 is above the 20-day moving average (MA) of 1.22, above the 50-day MA of 1.19, and below the 200-day MA of 1.89, indicating a neutral trend. The MACD of 0.06 indicates Negative momentum. The RSI at 48.46 is Neutral, neither overbought nor oversold. The STOCH value of 57.82 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for RAPT.

RAPT Therapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
TNXP	59 Neutral	$129.79M	―	-106.12%	―	29.94%	-241.81%
BCRX	52 Neutral	$1.64B	―	18.68%	―	36.00%	63.50%
Sector *	49 Neutral	$6.85B	0.81	-52.91%	2.50%	19.94%	1.20%
RAPT	46 Neutral	$161.05M	―	-77.09%	―	―	-2.29%
ARVN	44 Neutral	$521.98M	―	-35.41%	―	-39.92%	7.38%
CARA	44 Neutral	$23.55M	―	-270.01%	―	-65.96%	40.80%
FATE	42 Neutral	$97.33M	―	-54.21%	―	-78.55%	-0.92%

RAPT Therapeutics Corporate Events

RAPT Therapeutics Announces Board Restructuring in 2025

On March 21, 2025, Dr. Wendye R. Robbins informed RAPT Therapeutics’ Board of Directors that she will not seek re-election at the company’s 2025 annual meeting, marking the end of her tenure. Subsequently, on March 25, 2025, the Board decided to reduce its size from six to five members, effective at the annual meeting.

RAPT Therapeutics Plans Phase 2b Trials for RPT904

RAPT Therapeutics announced plans to initiate Phase 2b trials for RPT904 in food allergy by the second half of 2025 and Phase 2 or 3 trials for chronic spontaneous urticaria in 2026, projecting significant revenue potential in these markets. The company aims to offer improved dosing frequency and better compliance over existing treatments, positioning RPT904 as a potential best-in-class option, which could enhance their market presence and provide substantial commercial upside.

RAPT Therapeutics Announces Leadership Changes and Realignment

RAPT Therapeutics announced that William Rieflin has resigned from its Board of Directors, with Lori Lyons-Williams appointed as the new Chair. The Board has reduced its size to six directors and added Linda Kozick to the Audit Committee, indicating a strategic realignment in leadership and governance.